Payment overview · 2025
General Payments
$372.42
28 reported records · 6 companies
Healthcare provider profile · identity verified
James E Seeley, MD
Allopathic & Osteopathic Physicians|Family Medicine · OLD HICKORY, TN · NPI 1568448736
Verified facts
What the public records show
CMS Open Payments records show James E Seeley, MD received $372.42 in general payments during 2025 across 28 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 55.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $204.71 | 55.0% | 20 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $48.55 | 13.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.17 | 11.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.63 | 9.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.22 | 6.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.14 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $372.42 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $204.71 | 20 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $48.55 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.17 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.17 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.63 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 394 | 112 |
| Lisinopril | Lisinopril | 364 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 314 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 308 | 76 |
| Gabapentin | Gabapentin | 280 | 68 |
| Omeprazole | Omeprazole | 241 | 66 |
| Furosemide | Furosemide | 218 | 59 |
| Losartan Potassium | Losartan Potassium | 199 | 60 |
| Potassium Chloride | Potassium Chloride | 179 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 48 |
| Trazodone Hcl | Trazodone Hcl | 143 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 35 |
| Famotidine | Famotidine | 131 | 42 |
| Meloxicam | Meloxicam | 121 | 34 |
| Metformin Hcl | Metformin Hcl | 119 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 27 |
| Carvedilol | Carvedilol | 106 | 21 |
| Pregabalin | Pregabalin | 104 | 30 |
| Simvastatin | Simvastatin | 104 | 28 |
| Tramadol Hcl | Tramadol Hcl | 103 | 27 |
| Memantine Hcl | Memantine Hcl | 100 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 30 |
| Donepezil Hcl | Donepezil Hcl | 93 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 32 |
| Finasteride | Finasteride | 90 | 28 |
| Buspirone Hcl | Buspirone Hcl | 89 | 29 |
| Alprazolam | Alprazolam | 85 | 24 |
| Methylprednisolone | Methylprednisolone | 85 | 61 |
| Alendronate Sodium | Alendronate Sodium | 82 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 22 |
| Celecoxib | Celecoxib | 79 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 23 |
| Ozempic | Semaglutide | 77 | 16 |
| Farxiga | Dapagliflozin Propanediol | 74 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 71 | 23 |
| Montelukast Sodium | Montelukast Sodium | 71 | 23 |
| Sertraline Hcl | Sertraline Hcl | 71 | 21 |
| Eliquis | Apixaban | 67 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 12 |
| Cefdinir | Cefdinir | 62 | 53 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 11 |
| Clonidine Hcl | Clonidine Hcl | 60 | 17 |
| Lorazepam | Lorazepam | 60 | suppressed |
| Lovastatin | Lovastatin | 58 | 16 |
| Allopurinol | Allopurinol | 55 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 13 |
| Xarelto | Rivaroxaban | 54 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 26 |
| Metformin Hcl Er | Metformin Hcl | 48 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 38 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 13 |
| Jardiance | Empagliflozin | 44 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 11 |
| Estradiol | Estradiol | 43 | 11 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 13 |
| Fluconazole | Fluconazole | 40 | 14 |
| Meclizine Hcl | Meclizine Hcl | 40 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 31 |
| Baclofen | Baclofen | 37 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Prednisone | Prednisone | 34 | 20 |
| Glipizide | Glipizide | 33 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 14 |
| Rybelsus | Semaglutide | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Colchicine | Colchicine | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $372.42 · 28 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | FARXIGA, INGREZZA, Leqembi, NURTEC ODT, TRELEGY ELLIPTA, XIFAXAN, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error